Wall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should KnowZacks Investment Research • 07/22/24
Here's Why 'Trend' Investors Would Love Betting on Immatics (IMTX)Zacks Investment Research • 07/22/24
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialGlobeNewsWire • 11/08/23
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T MonotherapyGlobeNewsWire • 10/24/23
Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)Zacks Investment Research • 10/12/23
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of DirectorsPRNewsWire • 09/12/23
Immatics inks deal worth $120M to $1.7B with Moderna to boost cancer vaccine developmentProactive Investors • 09/11/23
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsGlobeNewsWire • 09/11/23
Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsAccesswire • 09/11/23
How Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%Zacks Investment Research • 08/21/23
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid TumorsGlobeNewsWire • 08/10/23